Anzeige
Mehr »
Login
Dienstag, 19.03.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Mega-Kurskatalysator - Vorbereitung der Phase-3 Studie soeben bestätigt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 881535 | ISIN: US75886F1075 | Ticker-Symbol: RGO
Tradegate
18.03.24
17:49 Uhr
888,50 Euro
+5,00
+0,57 %
1-Jahres-Chart
REGENERON PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
REGENERON PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
880,50887,0012:01
880,50887,0012:01

Aktuelle News zur REGENERON PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoAppeals Court Revives Regeneron's Antitrust Lawsuit Against Novartis Over Vision Treatment5
MoUS appeals court revives Regeneron's antitrust lawsuit against Novartis10
FrRegeneron EVP research sells over $5.5 million in stock5
FrUnpacking the Latest Options Trading Trends in Regeneron Pharmaceuticals2
DoRegeneron's Praluent receives FDA approval for paediatric patients with genetic high cholesterol4
MiRegeneron sees modest stock PT rise to $1,115 from $1,104 at Morgan Stanley4
MiRegeneron Pharmaceuticals, Inc.: High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization3
12.03.Regeneron (REGN) Gets FDA Nod for Praluent Label Extension2
12.03.Pro Research: Wall Street dives into Regeneron's robust prospects2
11.03.Regeneron shares gain as Bernstein starts with Outperform3
11.03.Regeneron's Praluent injection gets FDA approval to treat kids with genetic form of high cholesterol3
11.03.Regeneron Announces FDA Approval Extending Treatment Of Praluent To Children Aged 8157WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals, Inc. (REGN) announced the FDA has extended the approval of Praluent as an adjunct to diet and other low-density lipoprotein cholesterol lowering...
► Artikel lesen
11.03.Regeneron Pharmaceuticals, Inc.: Praluent (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol112TARRYTOWN, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the U.S. Food & Drug Administration (FDA) has extended the approval of Praluent® (alirocumab)...
► Artikel lesen
08.03.Regeneron Pharmaceuticals, Inc.: EYLEA HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet95Published results show EYLEA HD with extended 12- or 16-week dosing regimens demonstrated non-inferior vision gains to standard of care EYLEA® (aflibercept) Injection 2 mg with fixed 8-week dosing...
► Artikel lesen
01.03.Decoding Regeneron Pharmaceuticals' Options Activity: What's the Big Picture?7
01.03.GENESIS Pharma kündigt exklusive Vertriebsvereinbarung mit Regeneron Pharmaceuticals zur Vermarktung von Cemiplimab in Griechenland, Zypern und Malta an299Cemiplimab ist ein wirksamer PD-1-Inhibitor, der von der Europäischen Arzneimittelagentur für bestimmte Patienten mit fortgeschrittenem Basalzellkarzinom, fortgeschrittenem Plattenepithelkarzinom...
► Artikel lesen
01.03.GENESIS Pharma Announces an Exclusive Distribution Agreement With Regeneron Pharmaceuticals to Commercialize cemiplimab in Greece, Cyprus and Malta274Cemiplimab is an effective PD-1 inhibitor approved by the European Medicines Agency for certain patients with advanced basal cell carcinoma, advanced cutaneous squamous cell carcinoma, advanced...
► Artikel lesen
23.02.FDA to decide on Sanofi/Regeneron's Dupixent for COPD in June11
23.02.Sanofi, Regeneron win FDA priority review for Dupixent label expansion9
23.02.Sanofi, Regeneron get a step closer on Dupixent COPD nod with FDA priority review4
Seite:  Weiter >>
310 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1